Drug and Therapeutics Bulletin 1996;34:69-70; doi:10.1136/dtb.1996.34969
Copyright © 1996 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

{blacktriangledown}Pylorid, H. pylori and peptic ulcer

Relevant BNF section: 1.3.1

In most people with a duodenal or gastric ulcer, the stomach mucosa is infected with Helicobacter pylori.1 If this infection is eradicated the risk of ulcer relapse is greatly reduced. Ranitidine bismuth citrate (Pylorid - GlaxoWellcome) was licensed last year and promoted as a drug "designed to be used in combination with clarithromycin for effective eradication of H. pylori". How valuable is it in the management of peptic ulcer disease?






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1996 BMJ Publishing Group Ltd.